Home > Insider Trading > Filing (0001127602-12-008999)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1097264	Allos Therapeutics Inc	ALTH	Pharmaceutical Preparations (2834)	541655029

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1500560	E Michael Schick	11080 Circlepoint Road Suite 200 Westminster CO 80020	Vp, Sales And Marketing	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2012-02-28	135,545	$0.00	293,664	No	4	A	Direct
Common Stock	Disposition	2012-02-29	3,894	$1.52	289,770	No	4	S	Direct
Common Stock	Disposition	2012-03-01	3,960	$1.48	285,810	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

Represents shares of common stock issued as restricted stock units ("RSUs") awarded under the Company's 2008 Equity Incentive Plan (the "Plan"). The RSUs shall vest in a series of eight (8) successive equal semi-annual installments over the four (4)-year period measured from March 18, 2012 (the "Vesting Commencement Date"), subject to Participant's Continuous Service through each such date.
These shares are being sold pursuant to a 10b5-1 plan for Michael E. Schick in order to cover the withholding tax and other costs associated with such sale (i.e., wire fees, commission or interest) in connection with the vesting of restricted stock units on February 28, 2012.
The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $1.52 to $1.54. Upon request of the SEC staff, Allos Therapeutics, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price.
The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $1.48 to $1.49. Upon request of the SEC staff, Allos Therapeutics, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price.